A Successful, Evolving Model For Fund Governance

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.

On 30 September 2026, the SEC proposed rule amendments advancing Chairman Paul S. Atkins’ “responsible retailization” of private markets, expanding retail access to private-market strategies while adding key investor safeguards.

As we look ahead to 2025, the landscape of debt financing and M&A activity is poised for significant transformation.

What Every Owner Needs to Know Before Signing on the Dotted Line

Law firms are one of the last major professional services segments without meaningful private equity (PE) penetration.

Simpson Thacher Sustainability And ESG: Regulatory Update – September 2026

The European Union's Cyber Resilience Act introduces mandatory cybersecurity requirements for software and connected hardware sold in the EU market, with vulnerability reporting obligations beginning September 2026...

SEC-registered investment advisers are subject to an array of reporting and compliance obligations in order to maintain registered investment adviser status.

State legislatures across the U.S. have enacted a complex web of AI regulations affecting private sector businesses, spanning employment decisions, healthcare applications, consumer interactions, and digital rights. These laws impose compliance obligations including bias audits, disclosure requirements, and restrictions on automated decision-making, with enforcement mechanisms ranging from regulatory oversight to private rights of action. Understanding which state laws apply to your AI systems is critical,

As we look ahead to 2025, the landscape of debt financing and M&A activity is poised for significant transformation.

On June 1, 2023, China's Ministry of Science and Technology (the "MOST") issued the long-awaited Implementing Rules on the Administrative Regulations on Human Genetic Resources...

A sentencing hearing is scheduled before U.S. District Court Judge Loretta A. Preska on March 19, 2019.

Yesterday saw another big addition to the U.S. UFLPA Entity List, the largest to date. The Department of Homeland Security, on behalf of the Forced Labor Enforcement Task Force...

On 31 October 2025, the Financial Conduct Authority (FCA) published the outcome of a multi-firm review into consolidation across the financial advice and wealth management sector.

The UK National Crime Agency (NCA) has successfully defended the first challenge to its new power to require individuals to explain how they have acquired assets which it suspects may represent the proceeds of crime.

In the United States Supreme Court’s historic decision announced today, the Patient Protection and Affordable Care Act ("ACA") has emerged substantially intact as the blueprint for national health reform in the coming years.

Extradition from Japan is rare, and even more so for Japanese nationals in connection with white collar offenses. But on April 17, 2019,

China will launch further reforms in the pharmaceutical sector as part of the healthcare reform initiatives announced by the State Council in its February 9, 2017 Circular on Several Opinions Concerning Further Reforms of the Policies Governing Drug Production, Circulation and Usage (the "Circular No.13").

Today, the Patent Trial & Appeal Bord designated two decisions informative that apply the so-called "Fintiv factors."